Phase I clinical trials in patients with advanced non-small cell lung cancer treated within a Drug Development Unit: What have we learnt?

[1]  Y. Shentu,et al.  Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. , 2016, The New England journal of medicine.

[2]  Y. Shentu,et al.  Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial , 2016, The Lancet.

[3]  C. Rudin,et al.  Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.

[4]  L. Crinò,et al.  Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.

[5]  J. Lunceford,et al.  Pembrolizumab for the treatment of non-small-cell lung cancer. , 2015, The New England journal of medicine.

[6]  P. Jänne,et al.  AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. , 2015, The New England journal of medicine.

[7]  J. Neal,et al.  Rociletinib in EGFR-mutated non-small-cell lung cancer. , 2015, The New England journal of medicine.

[8]  L. Sequist,et al.  Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. , 2015, The Lancet. Oncology.

[9]  Chun-Ming Tsai,et al.  Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  Robert Brian Jenkins,et al.  Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology , 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[11]  Michael Thomas,et al.  Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. , 2013, The New England journal of medicine.

[12]  P. Jänne,et al.  Pooled analysis of the prognostic and predictive effects of KRAS mutation status and KRAS mutation subtype in early-stage resected non-small-cell lung cancer in four trials of adjuvant chemotherapy. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  D. Fairclough,et al.  Symptom and Quality of Life Benefit of Afatinib in Advanced Non–Small-Cell Lung Cancer Patients Previously Treated with Erlotinib or Gefitinib: Results of a Randomized Phase IIb/III Trial (LUX-Lung 1) , 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[14]  F Levi,et al.  European cancer mortality predictions for the year 2012. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[15]  R. Plummer,et al.  Patient selection for oncology phase I trials: a multi-institutional study of prognostic factors. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  E. Felip,et al.  Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. , 2012, The Lancet. Oncology.

[17]  S. Teerenstra,et al.  Reply letter to: pitfalls and limitations of a single-centre, retrospectively derived prognostic score for phase I oncology trial participant - reply to Füssenich et al.: a new, simple and objective prognostic score for phase I cancer patients. , 2012, European journal of cancer.

[18]  B. Kholodenko,et al.  Cross-talk between mitogenic Ras/MAPK and survival PI3K/Akt pathways: a fine balance. , 2012, Biochemical Society transactions.

[19]  P. Workman,et al.  Exploiting the cancer genome: strategies for the discovery and clinical development of targeted molecular therapeutics. , 2012, Annual review of pharmacology and toxicology.

[20]  S. Digumarthy,et al.  Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[21]  Jun Ma,et al.  Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. , 2011, The Lancet. Oncology.

[22]  J. Blenis,et al.  The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation. , 2011, Trends in biochemical sciences.

[23]  C. Mathers,et al.  Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 , 2010, International journal of cancer.

[24]  Jeffrey W. Clark,et al.  Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. , 2010, The New England journal of medicine.

[25]  Paul Workman,et al.  Envisioning the future of early anticancer drug development , 2010, Nature Reviews Cancer.

[26]  Paul D. Smith,et al.  The First-in-Human Study of the Hydrogen Sulfate (Hyd-Sulfate) Capsule of the MEK1/2 Inhibitor AZD6244 (ARRY-142886): A Phase I Open-Label Multicenter Trial in Patients with Advanced Cancer , 2010, Clinical Cancer Research.

[27]  Miklos Pless,et al.  Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  J. Dancey,et al.  Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  Lucio Crinò,et al.  Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study. , 2013, The Lancet. Oncology.

[30]  S. Kaye,et al.  Pitfalls and limitations of a single-centre, retrospectively derived prognostic score for phase I oncology trial participants - reply to Fussenich et al.: a new, simple and objective prognostic score for phase I cancer patients. , 2012, European journal of cancer.